Although EGFR represents one of the most investigated molecular targets in ESCC, in recent clinical trials, combination treatment with anti EGFR antibody and radiotherapy or conventional chemotherapy failed to show the additional treatment efficacy [4–6]. Here, EGFR is linked to esophageal squamous cell carcinoma.